Nomogram development and validation to predict Ki-67 expression of hepatocellular carcinoma derived from Gd-EOB-DTPA-enhanced MRI combined with T1 mapping
ObjectiveAs an important biomarker to reflect tumor cell proliferation and tumor aggressiveness, Ki-67 is closely related to the high early recurrence rate and poor prognosis, and pretreatment evaluation of Ki-67 expression possibly provides a more accurate prognosis assessment and more better treat...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.954445/full |
| _version_ | 1811213916437479424 |
|---|---|
| author | Ziwei Liu Shaomin Yang Shaomin Yang Xinjie Chen Chun Luo Jieying Feng Haixiong Chen Fusheng Ouyang Rong Zhang Xiaohong Li Wei Liu Baoliang Guo Qiugen Hu |
| author_facet | Ziwei Liu Shaomin Yang Shaomin Yang Xinjie Chen Chun Luo Jieying Feng Haixiong Chen Fusheng Ouyang Rong Zhang Xiaohong Li Wei Liu Baoliang Guo Qiugen Hu |
| author_sort | Ziwei Liu |
| collection | DOAJ |
| description | ObjectiveAs an important biomarker to reflect tumor cell proliferation and tumor aggressiveness, Ki-67 is closely related to the high early recurrence rate and poor prognosis, and pretreatment evaluation of Ki-67 expression possibly provides a more accurate prognosis assessment and more better treatment plan. We aimed to develop a nomogram based on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) combined with T1 mapping to predict Ki-67 expression in hepatocellular carcinoma (HCC).MethodsThis two-center study retrospectively enrolled 148 consecutive patients who underwent preoperative Gd-EOB-DTPA-enhanced MRI T1 mapping and surgically confirmed HCC from July 2019 to December 2020. The correlation between quantitative parameters from T1 mapping, ADC, and Ki-67 was explored. Three cohorts were constructed: a training cohort (n = 73) and an internal validation cohort (n = 31) from Shunde Hospital of Southern Medical University, and an external validation cohort (n = 44) from the Sixth Affiliated Hospital, South China University of Technology. The clinical variables and MRI qualitative and quantitative parameters associational with Ki-67 expression were analyzed by univariate and multivariate logistic regression analyses. A nomogram was developed based on these associated with Ki-67 expression in the training cohort and validated in the internal and external validation cohorts.ResultsT1rt-Pre and T1rt-20min were strongly positively correlated with Ki-67 (r = 0.627, r = 0.607, P < 0.001); the apparent diffusion coefficient value was moderately negatively correlated with Ki-67 (r = -0.401, P < 0.001). Predictors of Ki-67 expression included in the nomogram were peritumoral enhancement, peritumoral hypointensity, T1rt-20min, and tumor margin, while arterial phase hyperenhancement (APHE) was not a significant predictor even included in the regression model. The nomograms achieved good concordance indices in predicting Ki-67 expression in the training and two validation cohorts (0.919, 0.925, 0.850), respectively.ConclusionsT1rt-Pre and T1rt-20min had a strong positive correlation with the Ki-67 expression in HCC, and Gd-EOB-DTPA enhanced MRI combined with T1 mapping-based nomogram effectively predicts high Ki-67 expression in HCC. |
| first_indexed | 2024-04-12T05:54:20Z |
| format | Article |
| id | doaj.art-c3c236c677af41e89c751e2fa4adb901 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T05:54:20Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-c3c236c677af41e89c751e2fa4adb9012022-12-22T03:45:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-10-011210.3389/fonc.2022.954445954445Nomogram development and validation to predict Ki-67 expression of hepatocellular carcinoma derived from Gd-EOB-DTPA-enhanced MRI combined with T1 mappingZiwei Liu0Shaomin Yang1Shaomin Yang2Xinjie Chen3Chun Luo4Jieying Feng5Haixiong Chen6Fusheng Ouyang7Rong Zhang8Xiaohong Li9Wei Liu10Baoliang Guo11Qiugen Hu12Department of Radiology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, ChinaDepartment of Radiology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, ChinaDepartment of Radiology, The Affiliated Shunde Hospital of Guangzhou Medical University, Foshan, ChinaDepartment of Radiology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, ChinaDepartment of Radiology, The First People’s Hospital of Foshan, Foshan, ChinaDepartment of Radiology, The Sixth Affiliated Hospital, South China University of Technology, Foshan, ChinaDepartment of Radiology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, ChinaDepartment of Radiology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, ChinaDepartment of Radiology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, ChinaDepartment of Radiology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, ChinaDepartment of Radiology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, ChinaDepartment of Radiology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, ChinaDepartment of Radiology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, ChinaObjectiveAs an important biomarker to reflect tumor cell proliferation and tumor aggressiveness, Ki-67 is closely related to the high early recurrence rate and poor prognosis, and pretreatment evaluation of Ki-67 expression possibly provides a more accurate prognosis assessment and more better treatment plan. We aimed to develop a nomogram based on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) combined with T1 mapping to predict Ki-67 expression in hepatocellular carcinoma (HCC).MethodsThis two-center study retrospectively enrolled 148 consecutive patients who underwent preoperative Gd-EOB-DTPA-enhanced MRI T1 mapping and surgically confirmed HCC from July 2019 to December 2020. The correlation between quantitative parameters from T1 mapping, ADC, and Ki-67 was explored. Three cohorts were constructed: a training cohort (n = 73) and an internal validation cohort (n = 31) from Shunde Hospital of Southern Medical University, and an external validation cohort (n = 44) from the Sixth Affiliated Hospital, South China University of Technology. The clinical variables and MRI qualitative and quantitative parameters associational with Ki-67 expression were analyzed by univariate and multivariate logistic regression analyses. A nomogram was developed based on these associated with Ki-67 expression in the training cohort and validated in the internal and external validation cohorts.ResultsT1rt-Pre and T1rt-20min were strongly positively correlated with Ki-67 (r = 0.627, r = 0.607, P < 0.001); the apparent diffusion coefficient value was moderately negatively correlated with Ki-67 (r = -0.401, P < 0.001). Predictors of Ki-67 expression included in the nomogram were peritumoral enhancement, peritumoral hypointensity, T1rt-20min, and tumor margin, while arterial phase hyperenhancement (APHE) was not a significant predictor even included in the regression model. The nomograms achieved good concordance indices in predicting Ki-67 expression in the training and two validation cohorts (0.919, 0.925, 0.850), respectively.ConclusionsT1rt-Pre and T1rt-20min had a strong positive correlation with the Ki-67 expression in HCC, and Gd-EOB-DTPA enhanced MRI combined with T1 mapping-based nomogram effectively predicts high Ki-67 expression in HCC.https://www.frontiersin.org/articles/10.3389/fonc.2022.954445/fullGd-EOB-DTPAT1 mappinghepatocellular carcinomaKi-67nomogram |
| spellingShingle | Ziwei Liu Shaomin Yang Shaomin Yang Xinjie Chen Chun Luo Jieying Feng Haixiong Chen Fusheng Ouyang Rong Zhang Xiaohong Li Wei Liu Baoliang Guo Qiugen Hu Nomogram development and validation to predict Ki-67 expression of hepatocellular carcinoma derived from Gd-EOB-DTPA-enhanced MRI combined with T1 mapping Frontiers in Oncology Gd-EOB-DTPA T1 mapping hepatocellular carcinoma Ki-67 nomogram |
| title | Nomogram development and validation to predict Ki-67 expression of hepatocellular carcinoma derived from Gd-EOB-DTPA-enhanced MRI combined with T1 mapping |
| title_full | Nomogram development and validation to predict Ki-67 expression of hepatocellular carcinoma derived from Gd-EOB-DTPA-enhanced MRI combined with T1 mapping |
| title_fullStr | Nomogram development and validation to predict Ki-67 expression of hepatocellular carcinoma derived from Gd-EOB-DTPA-enhanced MRI combined with T1 mapping |
| title_full_unstemmed | Nomogram development and validation to predict Ki-67 expression of hepatocellular carcinoma derived from Gd-EOB-DTPA-enhanced MRI combined with T1 mapping |
| title_short | Nomogram development and validation to predict Ki-67 expression of hepatocellular carcinoma derived from Gd-EOB-DTPA-enhanced MRI combined with T1 mapping |
| title_sort | nomogram development and validation to predict ki 67 expression of hepatocellular carcinoma derived from gd eob dtpa enhanced mri combined with t1 mapping |
| topic | Gd-EOB-DTPA T1 mapping hepatocellular carcinoma Ki-67 nomogram |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.954445/full |
| work_keys_str_mv | AT ziweiliu nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT shaominyang nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT shaominyang nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT xinjiechen nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT chunluo nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT jieyingfeng nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT haixiongchen nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT fushengouyang nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT rongzhang nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT xiaohongli nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT weiliu nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT baoliangguo nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping AT qiugenhu nomogramdevelopmentandvalidationtopredictki67expressionofhepatocellularcarcinomaderivedfromgdeobdtpaenhancedmricombinedwitht1mapping |